Duocarmycin SA Reduces Proliferation and Increases Apoptosis in Acute Myeloid Leukemia Cells In Vitro

Area of Science:

• Hematology
• Cancer Biology
• Molecular Pharmacology

Background:

• Acute myeloid leukemia (AML) is a serious blood cancer with a poor prognosis despite current treatments.
• There is an urgent need for novel therapeutic agents to improve outcomes for AML patients.

Purpose of the Study:

• To investigate the efficacy of Duocarmycin Stable A (DSA) as a potential treatment for AML.
• To determine if DSA induces DNA damage and cytotoxicity in AML cells at low concentrations.

Main Methods:

• Utilized human AML cell lines (Molm-14, HL-60) for in vitro studies.
• Performed assays including MTT, DNA double-strand breaks (DSBs) analysis, cell cycle analysis, EdU incorporation, colony formation assays, Annexin V staining, and RNA sequencing.

Main Results:

• DSA treatment resulted in significant DNA DSBs and G2M cell cycle arrest in AML cells.
• DSA reduced AML cell proliferation and induced apoptosis.
• RNA sequencing revealed that DSA modulates genes involved in DNA repair, cell cycle control, and apoptosis.

Conclusions:

• Duocarmycin Stable A demonstrates potent anti-leukemic activity in vitro.
• DSA's ability to induce DNA damage and apoptosis makes it a promising candidate for further development in AML therapy.